RESUMO
BACKGROUND/AIM: To determine the anti-hyperglycemic effect of Euphorbia antiquorum L. root. MATERIALS AND METHODS: The study evaluates the anti-hyperglycemic effect of E. antiquorum root in streptozotocin-nicotinamide-induced Type 2 diabetes mellitus and fructose-induced insulin resistance models. Alcohol and aqueous extracts of E. antiquorum root were administered at doses 200 and 400 mg/kg p.o. Serum levels of glucose, total cholesterol, triglycerides, glycosylated hemoglobin (GHb), and hepatic levels of malondialdehyde, glutathione, and glycogen were estimated. RESULTS: Treatment with the alcohol and aqueous extracts of E. antiquorum roots resulted in significant (P < 0.001) lowering of serum blood glucose and GHb levels in both the models. Flavonoids, phenolic compounds, and glycosides were detected in the preliminary phytochemical screening. CONCLUSION: Root of E. antiquorum showed promising anti-hyperglycemic effect which may be due to the presence of important phytochemicals.
RESUMO
Lornoxicam is a selective cyclooxygenase-1 and cyclooxygenase-2 inhibitor that exhibits anti-inflammatory, analgesic, and antipyretic activities. It is used in osteoarthritis and rheumatoid arthritis; and in treatment of postoperative pain and primary dysmenorrhoea. Lornoxicam is completely insoluble in water but soluble in alkaline solutions. Hydrotropic solubilization is a technique used to increase the aqueous solubility of poorly water-soluble drugs and the present study was aimed at developing a hydrotropic technique to increase the solubility of lornoxicam, using 2 M sodium benzoate as the hydrotropic agent. Beer's law was obeyed in the concentration range of 4-24 µg/mL at 381 nm. The solubility of lornoxicam in distilled water considerably increased with the addition of a hydrotropic agent. The analysis of tablets indicated good correlation between the amounts estimated and label claim. The LOD and LOQ of lornoxicam were found to be 0.34 µg/mL and 1.038 µg/mL, respectively, indicating good sensitivity of the proposed method. The percentage recovery was found to be 99.99%-100.21%. Thus the proposed method is new, simple, environmentally friendly, accurate, and cost effective and can be successfully employed in routine analysis of lornoxicam in tablets.
RESUMO
The aim of this study was to investigate the use of inclusion complexation technique employing ß-cyclodextrin in improving the dissolution profile of candesartan cilexetil, a BCS class-II drug, and to formulate the inclusion complex into orodispersible tablets. The inclusion complexes were formed by physical mixing, kneading, coevaporation, and lyophilisation methods. Inclusion complexes were characterized by FTIR, DSC, XRD, NMR, and mass spectral studies. Inclusion complexes prepared using kneading, and lyophilisation techniques in the molar ratio 1 : 5 with ß-cyclodextrin were used for formulating orodispersible tablets by direct compression with different superdisintegrants like croscarmellose sodium, crospovidone, sodium starch glycolate, and low substituted hydroxypropyl cellulose in varying concentrations. The directly compressible powder was evaluated for precompression parameters, and the prepared orodispersible tablets were evaluated for postcompression parameters. Drug-excipient compatibility studies showed no interaction, and characterization proved the formation of inclusion complex. In vitro disintegration time was found to be within 3 minutes, and all the formulations showed complete drug release of 100% within 20 minutes. The optimized formulation was found to be stable after 6 months and showed no significant change in drug content. This work proved ß-cyclodextrins to be effective solubilizing agent in improving the solubility of poorly water soluble drugs.
